la jolla pharmaceuticals company
Posted September 13, 2011
By admin
La Jolla Pharmaceutical Corp. (LJPC) Video Stock Chart
|
|
La Jolla Pharmaceutical Company – Financial and Strategic Analysis Review $125.00 La Jolla Pharmaceutical Company – Financial and Strategic Analysis ReviewSummaryLa Jolla Pharmaceutical Company (La Jolla) is a biopharmaceutical Company engaged in developing pharmaceutical products to treat patients with lupus. The company’s lead product in development is Riquent, which is in Phase 3 ASPEN clinical trials to treat patients with lupus. The Lupus is an antibody-mediated disease ca… |
|
|
LA JOLLA REPORTS $66 MILLION PRIVATE PLACEMENT.: An article from: Biotech Financial Reports $5.95 This digital document is an article from Biotech Financial Reports, published by Thomson Gale on November 1, 2005. The length of the article is 552 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser.Citation DetailsTitle: L… |
|
|
LA JOLLA FILES REGISTRATION STATEMENT FOR PROPOSED MERGER.: An article from: Biotech Financial Reports $9.95 This digital document is an article from Biotech Financial Reports, published by Worldwide Videotex on January 1, 2010. The length of the article is 1494 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available immediately after purchase. You can view it with any web browser.Citation DetailsTitle: LA JOLLA FILES REGISTRATION S… |